SIGY Archives - BioTuesdays

Developments

CytoSorbents appears to validate Sigyn’s therapeutic strategy

CytoSorbents (NASDAQ:CTSO) has received a research grant from a division of the NIH to test the ability of its existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma, a...

November 10, 2022

Developments

Sigyn Therapeutics to register ChemoPrep and ChemoPure as trademarks for devices to enhance cancer therapy

Sigyn Therapeutics (OTCQB:SIGY) disclosed that trademark applications to register ChemoPrep and ChemoPure have been filed with the United States Patent and Trademark Office (USPTO). The intent-to-use trademark...

October 13, 2022

Developments

Sigyn Therapeutics files U.S. patent entitled “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”

Sigyn Therapeutics (OTCQB:SIGY) filed a provisional patent application entitled, “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity,” with the United States Patent and Trademark Office. Cancer is...

October 6, 2022

Executive Moves

Sigyn Therapeutics strengthens board with 3 appointments

Sigyn Therapeutics (OTCQB:SIGY) appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its board, effective Oct. 10, 2022. “As we transition toward the next phase of our clinical endeavors, it is an opportune...

October 4, 2022

Feature

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics (OTCQB:SIGY) has transitioned its Sigyn Therapy blood-purification device from conceptual design two years ago to preparing to initiate its first-in-human studies in end-stage renal disease patients...

October 4, 2022

Developments

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

Sigyn Therapeutics (OTCQB:SIGY) plans to pursue first-in-human feasibility studies of its Sigyn Therapy in end-stage renal disease (ESRD) patients suffering from excess inflammation and/or endotoxemia. Sigyn Therapy is...

September 14, 2022

Developments

Sigyn Therapeutics to begin trading on OTCQB today

Shares of Sigyn Therapeutics (OTCQB:SIGY) will begin trading on the OTCQB Venture Exchange at the market open today. The company’s securities, which previously traded on the OTC Pink Market, will continue to trade...

August 3, 2022

Executive Moves

Sigyn Therapeutics names hepatology leader Dr. Donald Hillebrand to SAB

Dr. Donald Hillebrand Sigyn Therapeutics (OTC:SIGY) appointed Dr. Donald Hillebrand, M.D., to its scientific advisory board. Dr. Hillebrand is the associate medical director of liver transplantation at Saint...

April 26, 2022

Executive Moves

Sigyn Therapeutics names neurology leader Dr. Ajay Verma to SAB

Ajay Verma Sigyn Therapeutics (OTC:SIGY) appointed Ajay Verma, M.D., Ph.D., a recognized thought leader in the field of neurology, to its scientific advisory board. Dr. Verma’s extensive clinical experience and insights...

March 31, 2022

Executive Moves

Sigyn Therapeutics names leading nephrologist Dr. H. David Humes to SAB

Sigyn Therapeutics (OTC:SIGY) appointed internationally recognized nephrologist, H. David Humes, M.D., to its scientific advisory board. Dr. Humes recently played an instrumental role in the oversight of preclinical...

March 15, 2022

Tag - SIGY

CytoSorbents appears to validate Sigyn’s therapeutic strategy

Sigyn Therapeutics to register ChemoPrep and ChemoPure as trademarks for devices to enhance cancer therapy

Sigyn Therapeutics files U.S. patent entitled “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”

Sigyn Therapeutics strengthens board with 3 appointments

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

Sigyn Therapeutics to begin trading on OTCQB today

Sigyn Therapeutics names hepatology leader Dr. Donald Hillebrand to SAB

Sigyn Therapeutics names neurology leader Dr. Ajay Verma to SAB

Sigyn Therapeutics names leading nephrologist Dr. H. David Humes to SAB

General

More